This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).
6 Primary · 9 Secondary · Reporting Duration: Time Frame: Start of OLTP to end of DBWP (7 weeks)
48 Total Participants · 2 Treatment Groups
Primary Treatment: Experimental: SDX · Has Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Global Medical Institutes LLC- Princeton Medical Institute||100.0%|